Agreement between Hikma and Civica to reduce US generic drug shortages

Home/Pharma News | Posted 23/08/2019 post-comment0 Post your comment

Hikma Pharmaceuticals Plc and Civica Rx announced a five-year agreement on 23 July 2019. Under the agreement, Hikma will manufacture and supply 14 essential sterile injectable medications for Civica. It will use Hikma's abbreviated new drug applications (ANDAs) and Civica's labelling and National Drug Code (NDC). The full list of medications included in the agreement, that are often in short supply in US hospitals, will be publicly announced in the near future. Initial shipments are expected by the end of 2019.

Drug Shortages FDA V13K15

Leading US hospital systems founded Civica [1] in 2018, to reduce chronic generic drug shortages in the US. It is a non-profit, non-stock corporation committed to stabilizing the supply of essential generic medications in hospitals. More than 30 health systems are Civica members and it currently represents approximately 30 per cent of all licensed US hospital beds.

The new agreement with Hikma, the third largest supplier of generic injectable medicines in the US, recognizes Hikma’s ability to deliver a large and consistent supply of quality injectable medicines. It will also take advantage of the significant investments made to expand their manufacturing capacity and capabilities. In recent years, the company has played a key role in launching medications to reduce drug shortages and in 2016 the company received a Drug Shortage Assistance Award from the US Food and Drug Administration for its role in preventing or alleviating drug shortages.

The five-year commitment from Civica guarantees demand and fair and sustainable pricing of the generic drug products. This will support Hikma and allow for effective production planning and more long-term manufacturing investments.

Related articles
Hikma launches HIV generic ritonavir in the US

Biosimilar deals for Hikma and Lupin

1. GaBI Online - Generics and Biosimilars Initiative. Hospitals launch non-profit generics company []. Mol, Belgium: Pro Pharma Communications International; [cited 2019 Aug 23]. Available from:

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2019 Pro Pharma Communications International. All Rights Reserved.

comment icon Comments (0)
Post your comment
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010